article · Inflammopharmacology

Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients

M Kamal
Rehab H. Werida
Safaa Ragab Askar
Mahasen A. Radwan
Gamal A. Omran
Marwa Adham El-Mohamdy
Radwa Samir Mohamed Hagag

202411 citationsOpen accessAin Shams University

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

This study is registered on ClinicalTrials.gov under the identifier NCT05291039. (You can access the study at https://clinicaltrials.gov/study/NCT05291039 (First Posted: March 22, 2022).

Research topics

Inflammatory Bowel Disease
Microscopic Colitis
Eosinophilic Esophagitis

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1007/s10787-024-01508-w

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.